METHODS FOR THE TREATMENT OF CARDIAC HYPERTROPHY

Methods for the treatment of cardiac hypertrophy are described. Additionally, the presently disclosed subject matter relates to the use of small molecule compounds for the inhibition of Human antigen R (HuR)-mRNA interaction, and more particularly for the reduction nuclear factor of activated T cell...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HE, Jie, YOSHIDA, George, STONE, Samuel, GABANIC, Andrew, TRANTER, Michael, ANTHONY, Sarah
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Methods for the treatment of cardiac hypertrophy are described. Additionally, the presently disclosed subject matter relates to the use of small molecule compounds for the inhibition of Human antigen R (HuR)-mRNA interaction, and more particularly for the reduction nuclear factor of activated T cells (NFAT) transcriptional activity. Novel methods of screening for small molecule compounds for inhibition of RNA binding proteins interaction with their target RNA (such as HuR-mRNA interactions) or for inhibition of DNA binding proteins to their target DNA are also described. La présente invention concerne des méthodes de traitement de l'hypertrophie cardiaque. L'invention concerne en outre l'utilisation de composés à petites molécules pour l'inhibition de l'interaction entre l'antigène humain R (HuR) et le mARN, et plus particulièrement pour la réduction de l'activité transcriptionnelle du facteur nucléaire des lymphocytes T activés (NFAT). L'invention porte en outre sur de nouveaux procédés de criblage de composés à petites molécules pour l'inhibition de l'interaction des protéines de liaison à l'ARN avec leur ARN cible (telles que des interactions HuR-mARN) ou pour l'inhibition de protéines de liaison d'ADN à leur ADN cible.